Patient-centered clinical trials prioritize the patient experience and outcomes that matter most to those affected by cancer. By centering on patient values and experiences, patient-centered outcomes research generates evidence to inform policies and practices, facilitating more personalized and effective cancer care. This manuscript explores the importance of patient-centered approaches in the global context, emphasizing challenges and opportunities for substantive patient engagement and the integration of patient-reported measures in clinical therapeutic trials in low- and middle-income countries. Despite important barriers such as limited infrastructure and funding constraints, leveraging innovative strategies and investing in research infrastructure and regulatory harmonization initiatives can enhance the capacity of low- and middle-income countries to conduct high-quality research and address the global burden of cancer more effectively. Through these efforts, patient-centered care and research can be extended to underserved populations, ensuring equitable access to cancer care worldwide.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848040 | PMC |
http://dx.doi.org/10.1093/jncimonographs/lgae043 | DOI Listing |
J Patient Rep Outcomes
March 2025
Department of Ophthalmology, Cornea Service, New England Eye Center and Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
Background: The Chronic Ocular Pain Questionnaire (COP-Q) is a newly developed patient-reported outcome (PRO) measure intended to assess symptoms and impacts associated with Chronic Ocular Surface Pain (COSP). This study assessed the psychometric properties of the COP-Q to determine the adequacy of the COP-Q as a 'fit-for-purpose' instrument to derive trial endpoints for future clinical studies in COSP.
Methods: Patients with COSP completed the COP-Q daily for four weeks on an electronic, touch-screen, tablet device as part of a longitudinal, observational study in the United States (N = 124).
JAMA Netw Open
March 2025
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill.
Importance: Frailty assessed at a single time point is associated with mortality in older women with breast cancer. Little is known about how changes in frailty following cancer treatment initiation affect mortality.
Objective: To evaluate the association between claims-based frailty trajectories following adjuvant chemotherapy initiation and 5-year mortality in older women with stage I to III breast cancer.
Cells
March 2025
Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA.
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy has prompted the development of multiple clinical trials addressing this question. This review seeks to outline and expand the current standard of care, as well as new advances, in the treatment of adult patients with ALL and address future areas of research.
View Article and Find Full Text PDFImmunol Rev
March 2025
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Asthma is one of the most prevalent and extensively studied chronic respiratory conditions, yet the heterogeneity of asthma remains biologically puzzling. Established factors like exogenous exposures and treatment adherence contribute to variability in asthma risk and clinical outcomes. It is also clear that the endogenous factors of genetics and immune system response patterns play key roles in asthma.
View Article and Find Full Text PDFInquiry
March 2025
Division of General Internal Medicine & Geriatrics, Oregon Health & Science University, Portland, OR, USA.
The Bundled Payment for Care Improvement Advanced (BPCI-A) model encourages value-based care by bundling 90-day healthcare-related costs into a single payment for eligible service codes and procedures for traditional Medicare Part A and B beneficiaries. Our institution, an Age-Friendly Health Systems Level 2 certified academic health center, participated in the BPCI-A model from 2018 to 2022. This study aimed to determine differences in days spent at home in the 30- and 90-day post-hospitalization period for older patients in the BPCI-A program based on Age-Friendly care status.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!